The new approval changes how Leqembi can be started, not who qualifies, what the drug can accomplish, or how closely treatment must be monitored. A person with mild cognitive impairment caused by Alzheimer’s disease may now be able to begin treatment with weekly injections at home instead of traveling for an intravenous infusion every two weeks. That person still needs confirmed amyloid pathology, a baseline brain MRI, specialist oversight, and follow-up scans for potentially serious brain swelling or bleeding. It also does not turn Leqembi into a cure, restore abilities already lost, or make the treatment appropriate for every stage of dementia.
Leqembi remains a disease-modifying therapy intended to slow decline in carefully selected adults at the mild cognitive impairment or mild dementia stage of Alzheimer’s disease. Families still have to weigh a limited clinical benefit against medical risks, treatment work, cost, and the person’s own priorities. The approval does offer a meaningful logistical alternative. The once-weekly starting regimen uses two 250-milligram autoinjectors for a total dose of 500 milligrams, compared with a weight-based intravenous infusion every two weeks. But bringing injections into the home relocates part of the treatment burden; it does not remove it.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Review the FDA’s approval and safety requirements for at-home Leqembi starting doses — Verify what the new approval changes and the monitoring and eligibility requirements that remain.
- Check Medicare’s Leqembi coverage and registry requirements — See the current CMS coverage criteria and patient-registry process for anti-amyloid treatment.
Table of Contents
- What Does the New Leqembi Starting-Dose Approval Actually Change?
- Eligibility for Early Alzheimer’s Disease Has Not Expanded
- Home Injection Does Not Remove ARIA Risk or MRI Monitoring
- Choosing At-Home Injection Versus IV Infusion
- Diagnosis, Access, and Caregiver Burden Still Shape Treatment
- Alzheimer’s Care Still Extends Beyond Amyloid Treatment
- Emergency Planning Remains Part of Leqembi Care
- Frequently Asked Questions
What Does the New Leqembi Starting-Dose Approval Actually Change?
The Food and Drug Administration approved leqembi IQLIK, the subcutaneous form of lecanemab, as a starting regimen in July 2026. Previously, patients began with intravenous Leqembi and could consider subcutaneous maintenance treatment after 18 months. The new option allows treatment to begin with 500 milligrams injected under the skin once a week, delivered as two 250-milligram injections. The intravenous starting option remains 10 milligrams per kilogram every two weeks, infused over approximately one hour. The current prescribing information also permits switching between the intravenous and subcutaneous routes under specific dosing schedules. After 18 months, a patient may continue a starting-dose regimen or transition to maintenance treatment.
The approved maintenance choices include a 360-milligram subcutaneous injection once a week or an intravenous infusion every four weeks. These are changes in delivery and scheduling, not evidence that one route produces a larger cognitive benefit than the other. The evidence supporting the at-home starting dose has an important limitation. According to the FDA's approval announcement, the subcutaneous formulation was not evaluated in a separate large clinical-outcome trial. Its approval relied on the established clinical evidence for intravenous Leqembi, along with findings that subcutaneous treatment produced equivalent drug exposure and similar amyloid-plaque reductions. A simpler route should therefore not be interpreted as a newly proven improvement in memory, independence, or survival.
Eligibility for Early Alzheimer’s Disease Has Not Expanded
Leqembi should still be initiated in people with mild cognitive impairment or mild dementia due to Alzheimer’s disease—the population studied in the clinical trials. Approval of a home injection did not extend treatment to people without symptoms, people with unconfirmed causes of cognitive decline, or people already living with moderate or severe dementia. There are no comparable trial data establishing the safety and effectiveness of starting Leqembi at those earlier or later stages. Amyloid pathology must be confirmed before treatment begins. Memory symptoms alone are not enough, because depression, medication effects, sleep disorders, vascular disease, thyroid problems, vitamin deficiencies, and other neurological conditions can produce similar difficulties.
For example, a person who repeatedly misplaces objects but has not completed an Alzheimer’s evaluation cannot be assumed to qualify simply because an autoinjector is available. The treatment goal also remains unchanged: slowing progression rather than reversing Alzheimer’s disease. In the pivotal intravenous trial, lecanemab produced a modest slowing of decline on cognitive and functional measures over 18 months. It did not stop the disease, return participants to their earlier level of functioning, or guarantee a noticeable benefit for every individual. A family may complete months of injections without seeing obvious day-to-day improvement, even when the treatment is having its intended statistical effect.
Home Injection Does Not Remove ARIA Risk or MRI Monitoring
Subcutaneous administration does not eliminate amyloid-related imaging abnormalities, or ARIA. ARIA can involve brain swelling, known as ARIA-E, or small areas of bleeding and iron deposition, known as ARIA-H. Many cases cause no symptoms and are found only on MRI, but serious or life-threatening events can occur. Reported symptoms include headache, confusion, dizziness, nausea, visual changes, difficulty walking, seizures, and focal neurological deficits. Patients still need a recent baseline brain MRI and scheduled monitoring scans after approximately one, two, three, and six months of treatment.
An additional MRI may be necessary if symptoms develop or a prior scan shows ARIA. This means that a person living far from an infusion center may save considerable travel by injecting at home but still needs reliable access to MRI facilities and clinicians who can review the images before treatment continues. Apolipoprotein E testing also remains important. People with two copies of the APOE ε4 variant have a higher incidence of ARIA, including symptomatic and severe cases, than people with one copy or no copies. The label says APOE ε4 testing should be performed before treatment to inform that risk, with counseling about the implications of genetic results. Anticoagulant use and evidence of previous brain microbleeds require particular caution; changing the route from a vein to the skin does not remove the drug’s effects within the brain’s blood vessels.
Choosing At-Home Injection Versus IV Infusion
The practical advantages of home treatment will vary. Someone who lives 90 minutes from an infusion center may prefer weekly injections because they avoid twice-monthly travel, intravenous access, and time in an infusion chair. Another person may prefer an infusion every two weeks because nurses administer the medicine, observe reactions, and take responsibility for dose preparation. Home treatment involves more frequent dosing and, during the starting phase, two injections on each treatment day. At-home administration is not meant to begin without instruction. The prescribing information states that therapy should start under a healthcare provider’s guidance and supervision.
Before a patient or caregiver takes over, the provider must give direct guidance for at least two consecutive subcutaneous doses and decide that home administration is appropriate. The clinician should periodically reassess that decision. Poor vision, tremor, arthritis, confusion, needle anxiety, or the absence of a dependable caregiver can make an autoinjector less practical than it appears. Home storage and injection routines add another tradeoff. The autoinjectors must be refrigerated, brought to room temperature for 20 minutes without an external heat source, inspected, and used at appropriate injection sites. Sites should be rotated, and injections should not be placed into bruised, tender, scarred, tattooed, or damaged skin. A household in which the patient manages medication alone despite worsening memory may need a locked storage area, a written dose log, and caregiver verification to reduce the risk of a missed or duplicate dose.
Diagnosis, Access, and Caregiver Burden Still Shape Treatment
The approval does not shorten the full pathway to treatment. Patients may still need cognitive testing, laboratory work, amyloid confirmation, genetic counseling, a medication review, MRI screening, and consultation with a clinician experienced in anti-amyloid therapy. In regions with few dementia specialists or limited MRI capacity, replacing infusion visits with home injections addresses only one part of the access problem. Insurance authorization, specialty-pharmacy distribution, copayments, and coverage for associated testing can also remain obstacles. Even when the medicine is covered, families may face expenses for appointments, imaging, transportation, respite care, or time away from work.
Approval establishes that a product may be marketed for a particular use; it does not guarantee that every health plan will cover every part of the care pathway promptly. Caregiver labor may change rather than disappear. A partner who once drove to an infusion clinic may now have to receive shipments, monitor refrigeration, prepare two devices each week, observe the injection sites, track doses, and watch for neurological symptoms. Local reactions can include redness, swelling, warmth, itching, pain, rash, bruising, nodules, or hematoma. Although many are limited to the injection site, severe reactions and reactions leading to treatment interruption have occurred.
Alzheimer’s Care Still Extends Beyond Amyloid Treatment
Leqembi does not replace the rest of dementia care. Patients may still need treatment for mood, sleep, hearing, vascular risk factors, or other illnesses that affect cognition and daily function. Depending on the individual, clinicians may also recommend established symptomatic Alzheimer’s medicines, occupational therapy, exercise, caregiver education, and changes that make the home safer.
For example, injections will not solve a developing problem with medication management, unpaid bills, unsafe driving, or a stove repeatedly left on. Those concerns require direct assessment and practical safeguards, such as supervised pill organization, financial protections, transportation planning, or automatic shutoff devices. Legal and advance-care planning also remains easier while the person can still express preferences and participate meaningfully in decisions.
Emergency Planning Remains Part of Leqembi Care
ARIA symptoms can resemble an ischemic stroke, which creates a specific emergency-care challenge. Sudden weakness, speech difficulty, severe confusion, seizure, visual loss, or an abrupt severe headache requires urgent evaluation.
Emergency clinicians should be told that the person receives lecanemab because brain imaging findings and the possibility of ARIA can affect decisions about clot-dissolving treatment. Families can keep a current medication list where emergency responders can find it and include the Leqembi formulation, dosing schedule, date of the most recent dose, anticoagulants or antiplatelet medicines, allergies, and the treating neurologist’s contact information. A copy can be placed in the patient’s wallet and another beside the household’s emergency information.
Frequently Asked Questions
Can anyone with an Alzheimer’s diagnosis start Leqembi injections at home?
No. Treatment should be initiated in adults with mild cognitive impairment or mild dementia due to Alzheimer’s disease, with confirmed amyloid pathology. Medical screening and a baseline MRI are still necessary.
Can the first injection be given without professional instruction?
No. Treatment begins under a healthcare provider’s guidance and supervision. The provider must give direct guidance for at least two consecutive subcutaneous doses before deciding that administration by the patient or caregiver is appropriate.
Is the at-home starting dose safer than intravenous Leqembi?
The overall safety profile is considered generally similar, and the risk of ARIA remains. Subcutaneous treatment adds the possibility of localized injection reactions, while intravenous treatment is associated with infusion-related reactions.
Does home dosing eliminate clinic visits?
It can reduce visits for drug administration, but it does not eliminate specialist appointments, baseline testing, scheduled MRIs, safety assessments, or visits prompted by symptoms.
Is the starting injection given once a week?
Yes. The approved subcutaneous starting dose is 500 milligrams once weekly, administered as two 250-milligram injections. After 18 months, a patient may continue the starting regimen or transition to an approved maintenance regimen.
Does Leqembi improve symptoms that have already developed?
Leqembi is intended to slow cognitive and functional decline. It is not approved as a cure and has not been shown to restore memory or independence already lost.
